Suppr超能文献

针对目前或既往患有抑郁症的吸烟者的戒烟干预措施。

Smoking cessation interventions for smokers with current or past depression.

作者信息

van der Meer Regina M, Willemsen Marc C, Smit Filip, Cuijpers Pim

机构信息

STIVORO, Dutch Expert Centre on Tobacco Control, The Hague, Netherlands.

出版信息

Cochrane Database Syst Rev. 2013 Aug 21(8):CD006102. doi: 10.1002/14651858.CD006102.pub2.

Abstract

BACKGROUND

Individuals with current or past depression are often smokers who are more nicotine dependent, more likely to suffer from negative mood changes after nicotine withdrawal, and more likely to relapse to smoking after quitting than the general population, which contributes to their higher morbidity and mortality from smoking-related illnesses. It remains unclear what interventions can help them to quit smoking.

OBJECTIVES

To evaluate the effectiveness of smoking cessation interventions, with and without specific mood management components, in smokers with current or past depression.

SEARCH METHODS

In April 2013, we searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, PsycINFO, other reviews, and asked experts for information on trials.

SELECTION CRITERIA

Criteria for including studies in this review were that they had to be randomised controlled trials (RCTs) comparing smoking cessation interventions in adult smokers with current or past depression. Depression was defined as major depression or depressive symptoms. We included studies where subgroups of participants with depression were identified, either pre-stated or post hoc. The outcome was abstinence from smoking after six months or longer follow-up. We preferred prolonged or continuous abstinence and biochemically validated abstinence where available.

DATA COLLECTION AND ANALYSIS

When possible, we estimated pooled risk ratios (RRs) with the Mantel-Haenszel method (fixed-effect model). We also performed subgroup analyses, by length of follow-up, depression measurement, depression group in study, antidepressant use, published or unpublished data, format of intervention, level of behavioural support, additional pharmacotherapy, type of antidepressant medication, and additional nicotine replacement therapy (NRT).

MAIN RESULTS

Forty-nine RCTs were included of which 33 trials investigated smoking cessation interventions with specific mood management components for depression. In smokers with current depression, meta-analysis showed a significant positive effect for adding psychosocial mood management to a standard smoking cessation intervention when compared with standard smoking cessation intervention alone (11 trials, N = 1844, RR 1.47, 95% CI 1.13 to 1.92). In smokers with past depression we found a similar effect (13 trials, N = 1496, RR 1.41, 95% CI 1.13 to 1.77). Meta-analysis resulted in a positive effect, although not significant, for adding bupropion compared with placebo in smokers with current depression (5 trials, N = 410, RR 1.37, 95% CI 0.83 to 2.27). There were not enough trial data to evaluate the effectiveness of fluoxetine and paroxetine for smokers with current depression. Bupropion (4 trials, N = 404, RR 2.04, 95% CI 1.31 to 3.18) might significantly increase long-term cessation among smokers with past depression when compared with placebo, but the evidence for bupropion is relatively weak due to the small number of studies and the post hoc subgroups for all the studies. There were not enough trial data to evaluate the effectiveness of fluoxetine, nortriptyline, paroxetine, selegiline, and sertraline in smokers with past depression.Twenty-three of the 49 trials investigated smoking cessation interventions without specific components for depression. There was heterogeneity between the trials which compared psychosocial interventions with standard smoking cessation counselling for both smokers with current and past depression. Therefore, we did not estimate a pooled effect. One trial compared nicotine replacement therapy (NRT) versus placebo in smokers with current depression and found a positive, although not significant, effect (N = 196, RR 2.64, 95% CI 0.93 to 7.45). Meta-analysis also found a positive, although not significant, effect for NRT versus placebo in smokers with past depression (3 trials, N = 432, RR 1.17, 95% CI 0.85 to 1.60). Three trials compared other pharmacotherapy versus placebo and six trials compared other interventions in smokers with current or past depression. Due to heterogeneity between the interventions of the included trials we did not estimate pooled effects.

AUTHORS' CONCLUSIONS: Evidence suggests that adding a psychosocial mood management component to a standard smoking cessation intervention increases long-term cessation rates in smokers with both current and past depression when compared with the standard intervention alone. Pooled results from four trials suggest that use of bupropion may increase long-term cessation in smokers with past depression. There was no evidence found for the use of bupropion in smokers with current depression. There was not enough evidence to evaluate the effectiveness of the other antidepressants in smokers with current or past depression. There was also not enough evidence to evaluate the group of trials that investigated interventions without specific mood management components for depression, including NRT and psychosocial interventions.

摘要

背景

目前或曾经患过抑郁症的人往往是吸烟者,他们对尼古丁的依赖性更强,尼古丁戒断后更易出现负面情绪变化,且戒烟后比普通人群更易复吸,这导致他们因吸烟相关疾病而具有更高的发病率和死亡率。目前尚不清楚哪些干预措施能帮助他们戒烟。

目的

评估有或无特定情绪管理成分的戒烟干预措施对目前或曾经患过抑郁症的吸烟者的有效性。

检索方法

2013年4月,我们检索了Cochrane对照试验中心注册库(CENTRAL)、MEDLINE、EMBASE、PsycINFO、其他综述,并向专家咨询试验相关信息。

入选标准

纳入本综述的研究标准为,必须是比较目前或曾经患过抑郁症的成年吸烟者戒烟干预措施的随机对照试验(RCT)。抑郁症定义为重度抑郁症或抑郁症状。我们纳入了那些事先设定或事后确定有抑郁症参与者亚组的研究。结局指标是随访6个月或更长时间后的戒烟情况。如有可能,我们更倾向于长期或持续戒烟以及经生化验证的戒烟。

数据收集与分析

在可能的情况下,我们采用Mantel-Haenszel方法(固定效应模型)估计合并风险比(RRs)。我们还按随访时间长度、抑郁症测量方法、研究中的抑郁症组、抗抑郁药使用情况、已发表或未发表数据、干预形式、行为支持水平、额外药物治疗、抗抑郁药物类型以及额外尼古丁替代疗法(NRT)进行了亚组分析。

主要结果

共纳入49项RCT,其中33项试验研究了针对抑郁症有特定情绪管理成分的戒烟干预措施。在目前患抑郁症的吸烟者中,荟萃分析显示,与单独的标准戒烟干预措施相比,在标准戒烟干预措施中增加心理社会情绪管理有显著的积极效果(11项试验,N = 1844,RR 1.47,95%CI 1.13至1.92)。在曾经患过抑郁症的吸烟者中我们发现了类似效果(13项试验,N = 1496,RR 1.41,95%CI 1.13至1.77)。荟萃分析显示,在目前患抑郁症的吸烟者中,与安慰剂相比,添加安非他酮有积极效果,但不显著(5项试验,N = 410,RR 1.37,95%CI 0.83至2.27)。没有足够的试验数据来评估氟西汀和帕罗西汀对目前患抑郁症的吸烟者的有效性。与安慰剂相比,安非他酮(4项试验,N = 404,RR 2.04,95%CI 1.31至3.18)可能会显著提高曾经患过抑郁症的吸烟者的长期戒烟率,但由于研究数量少且所有研究均为事后亚组分析,安非他酮的证据相对较弱。没有足够的试验数据来评估氟西汀、去甲替林、帕罗西汀、司来吉兰和舍曲林对曾经患过抑郁症的吸烟者的有效性。49项试验中有23项研究了没有针对抑郁症特定成分的戒烟干预措施。在比较心理社会干预与目前和曾经患过抑郁症的吸烟者的标准戒烟咨询的试验之间存在异质性。因此,我们没有估计合并效应。一项试验比较了目前患抑郁症的吸烟者中尼古丁替代疗法(NRT)与安慰剂,发现有积极效果,但不显著(N = 196,RR 2.64,95%CI 0.93至7.45)。荟萃分析还发现,在曾经患过抑郁症的吸烟者中,NRT与安慰剂相比有积极效果,但不显著(3项试验,N = 432,RR 1.17,95%CI 0.85至1.60)。三项试验比较了其他药物治疗与安慰剂,六项试验比较了目前或曾经患过抑郁症的吸烟者中的其他干预措施。由于纳入试验的干预措施之间存在异质性,我们没有估计合并效应。

作者结论

有证据表明,与单独的标准戒烟干预措施相比,在标准戒烟干预措施中增加心理社会情绪管理成分可提高目前和曾经患过抑郁症的吸烟者的长期戒烟率。四项试验的汇总结果表明,使用安非他酮可能会提高曾经患过抑郁症的吸烟者的长期戒烟率。没有证据表明安非他酮对目前患抑郁症的吸烟者有效。没有足够的证据来评估其他抗抑郁药对目前或曾经患过抑郁症的吸烟者的有效性。也没有足够的证据来评估研究没有针对抑郁症特定情绪管理成分的干预措施的试验组,包括NRT和心理社会干预措施。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验